Signal transducer and activator of transcription 4 (STAT4) is a transcription factor mainly activated by interleukin 12, which promotes the secretion of type 2 interferon (IFN) by T-helper 1 cells. We assessed the association of STAT4 gene polymorphism and primary Sjö gren's syndrome (pSS) and its functional relevance. We analyzed STAT4 rs7582694 polymorphism in an exploratory cohort of 186 pSS patients and 152 controls, and in a replication cohort of 192 pSS patients and 483 controls, all Caucasian. mRNA levels of STAT4a, STAT4b, STAT1, and the type 1 IFN-induced genes PKR, MX1 and IFITM1 were assessed in peripheral blood mononuclear cells (PBMCs) from 30 pSS patients. STAT4 rs7582694 C allele was associated with pSS in both cohorts (odds ratio (OR) 1.57, 95% confidence interval (CI) 1.27-1.93, P ¼ 2.3 Â 10
Introduction
Primary Sjö gren's syndrome (pSS) is a systemic autoimmune disease characterized by xerostomia and keratoconjunctivitis sicca due to lymphocytic infiltration of salivary and lachrymal glands. pSS and systemic lupus erythematosus share number of pathogenic mechanisms. Thus, the role of the interferon (IFN) pathway through an IFN signature, both in peripheral blood mononuclear cells (PBMCs) and in salivary glands, has been emphasized in pSS. [1] [2] [3] On the basis of the type of receptor through which they signal, human IFNs have been classified into three major types. Type I IFN bind to a specific cell surface receptor complex known as the IFNa receptor (IFNAR) that consists of IFNAR1 and IFNAR2 chains. The type I IFNs present in humans are IFNa, IFNb and IFNo. Downstream IFN-signaling pathway involves Janus kinase, which phosphorylates signal transducer and activator of transcription 1 (STAT1) and STAT2. The IFN-stimulated gene factor 3 complex containing STAT1 and STAT2 translocates to the nucleus and induces the transcription of IFN-dependent genes belonging to the IFN pathway. The IFN signature observed in pSS corresponds to increased expression of genes of this IFN pathway. Likewise, plasmacytoid dendritic cells, the professional cells secreting IFNa, are present in salivary glands, the target organ of the autoimmune process. These observations have provided new insights into the genetics of pSS by focusing on genes involved in innate immunity and the IFN pathway; the same interferon regulatory factor 5 (IRF5) polymorphism has been found associated with both pSS and systemic lupus erythematosus. [4] [5] [6] STAT4 is not classically considered as a factor involved in the type 1 IFN pathway. Conversely, it has a critical role in cellular growth and T-helper 1 differentiation, with interleukin 12 binding to its receptor. STAT4, a major specific factor in interleukin-12 signaling, is recruited and phosphorylated after cytokine stimulation to form homodimers that translocate to the nucleus, bind DNA and modulate gene transcription. STAT4 induces T-helper 1 factors, such as type 2 IFN (IFNg) and TNFa. Nevertheless, although not typically associated with the type 1 IFN pathway, STAT4 is activated after binding of type 1 IFN to IFNAR. Thus STAT4 could be at the crossroads of the type 1 and 2 IFN pathways. From a transcriptional point of view, STAT4 has alternatively spliced forms lacking the C-terminal amino acids of the transactivation domain. The full-length mRNA is referred to as STAT4a and the truncated form is designated STAT4b. Although STAT4a is functional, the functional role of STAT4b remains controversial.
Recently, two single nucleotide polymorphisms of STAT4 on chromosome 2q32.3 (rs7582694 and rs7574865, both in complete linkage disequilibrium (LD)), found to be genetic risk factors of systemic lupus erythematosus, were also reported to be associated with pSS. 6, 7 However, the functional consequence of this genetic association has not been studied in patients with pSS or with other autoimmune diseases. In the present study, we aimed to replicate the association between pSS and STAT4 polymorphism in two independent cohorts of patients with pSS. We studied the interaction between IRF5 and STAT4 polymorphism, searched for functional consequences of this genetic association and proposed a new hypothesis concerning the implications of STAT4 in the type 1 IFN response.
Results

STAT4 rs7582694 polymorphism is significantly associated with pSS
In the exploratory cohort, 27% of pSS patients, as compared with 17% of controls, exhibited the STAT4 rs7582694 C allele (odds ratio (OR) 1. 81, 95% confidence interval (CI) 1.24-2.62, P ¼ 2.3 Â 10 À3 ) ( Table 1 ). In the replication cohort, the frequency of the STAT4 rs7582694 C allele was 30% for pSS patients, which led to a confirmed significant association of STAT4 rs7582694 C allele with pSS (OR 1.56, 95% CI 1.19-2.03, P ¼ 1.4 Â 10 À3 ) ( Table 1 ). The overall OR for pSS for the combined cohorts was 1.57 (95% CI 1.27-1.93, P ¼ 2.3 Â 10 À5 ) ( Table 1 ). This OR was even higher when pSS patients and controls homozygous for the rs7582694 C allele were considered, which suggests a recessive effect of the STAT4 at-risk allele: OR 2.47 (95% CI 1.47-4.16, P ¼ 6 Â 10
À4
). The association was true for patients with and without anti-SSA/SSB antibodies, with no significant difference in genotype distribution between the two subgroups (P ¼ 0.28) (data not shown).
Additive effects of IRF5 and STAT4 risk allele in pSS susceptibility The CGGGG insertion in the promoter region of IRF5 was previously associated with pSS. The exploratory cohort was genotyped for this polymorphism, 4 which allowed for studying the effect of gene-gene interactions on susceptibility for pSS.
We used logistic regression to test different models explaining the risk of pSS as a function of IRF5 and STAT4 polymorphisms. A first set of logistic regression analyses were performed with the observed genotypes for IRF5 and STAT4. IRF5 genotypes were regrouped in three categories: 3R/3R (wild type), 3R/4R (heterozygotes) and 4R/4R (mutants). STAT4 genotypes were also treated as three categories, G/G (wild type), G/C (heterozygotes) and C/C (mutants). IRF5 and STAT4 atrisk genotypes were both strongly linked to the probability of developing pSS. For IRF5, results for the full model with the three categories and for a reduced model with regrouping of heterozygote and mutant subjects (carriers of at least one mutant allele) versus subjects with wild type did not differ significantly, which suggested a dominant effect of the risk allele. For STAT4, results for the full model with the three categories and for a reduced model with regrouping of heterozygote subjects and subjects with wild type (carriers of at least one wild-type allele) versus homozygote mutant subjects suggested a recessive effect of the risk allele. The interaction between IRF5 and STAT4 at-risk genotypes was not significant in the model, which suggested an independent additive effect of IRF5 and STAT4. Nevertheless, the power of detecting an interaction between both the genes was low suggesting that the present study would have only been able to detect an interaction of very high magnitude between both genes. Figure 1a shows the logarithm of the predicted OR in the different Genotype and allele distribution of the STAT4 rs7582694 polymorphism was inferred from the results of STAT4 rs7574865 genotyping performed in a French cohort of patients, owing to the complete linkage disequilibrium between both SNPs.
STAT4 gene polymorphism associated with Sjögren's syndrome N Gestermann et al groups with the corresponding CI in each group (the group without risk allele is taken as the reference); the gray dots represent the observed OR in each group. A second set of analyses were performed by entering the number of risk alleles (between 0 and 4) instead of the genotypes in the model and also showed the number of risk alleles significantly associated with the probability of developing pSS. Figure 1b illustrates this model: the dotted line and the black dots represent the logarithm of the OR predicted by the model versus the number of risk alleles, along with the corresponding CI, and the gray dots indicate the observed OR for each number of alleles. Table 2 shows the OR obtained for each of these models. The first logistic regression with an additive effect of the two genes showed a recessive effect of STAT4 C allele and a dominant effect of IRF5 4R allele. In the second model, we assume that each allele increased the risk by the same amount. When compared with Figure 1a , Figure 1b shows some model misfit for subjects with one risk allele suggesting that a model involving the effect of the two genes separately performs better.
Analysis of STAT4 mRNA expression by STAT4 rs7582694 genotypes STAT4a and STAT4b mRNA levels were assessed in PBMCs from 30 pSS patients. STAT4b mRNA level was about 10-fold lower than that of STAT4a, as was previously reported. 8 STATa and STAT4b mRNA levels in PBMCs were not associated with rs7582694 genotype (P ¼ 0.99 and P ¼ 0.17, respectively) (Figures 2a and b) . Analysis of STAT1 mRNA expression level by STAT4 rs7582694 genotype We hypothesized that STAT4 rs7582694 polymorphism could be in high LD with a functional polymorphism located in the nearby STAT1 locus. Thus, we assessed STAT1 mRNA level in STAT4 rs7582694 genotype, however, we found no significant association (Figure 2c ). mRNA levels of STAT4a and type 1 IFN-induced genes are strongly correlated Because STAT4 could be involved in type 1 IFN signalling, 9 we aimed to assess the potential correlation between the mRNA level of STAT4 and those of PKR, MX1 and IFITM1 as surrogate markers of the type 1 IFN induction pathway. We focused on the prominently expressed and functional subunit of STAT4, STAT4a. STAT4a mRNA expression was strongly correlated with that of type 1 IFN-induced genes:
, r ¼ 0.47) (Figure 3 ). This correlation was not observed for the mRNA levels of STAT4b and the type 1 IFN-induced genes (data not shown).
Discussion
In this study, we replicated the association of STAT4 polymorphism with pSS and found no relation with the mRNA level of STAT4a or STAT4b in PBMCs. However, we found a strong correlation between the mRNA levels of STAT4a and type 1 IFN-induced genes, which The gray dots correspond to the observed odds-ratio for each number of risk alleles. In total, 56 subjects were without a risk allele (17 with pSS) and 127 had one risk allele (75 with pSS), 110 had two risk alleles (61 with pSS), and 40 had three or four risk alleles (33 with pSS). The gray dots indicate the logarithm of the observed odds-ratio computed from the data for the corresponding number of risk alleles, with 0 being the reference group. We confirmed, in a French population of pSS patients, a significant association of the STAT4 rs7582694 C allele with pSS. Previous significant association of the allele with pSS was reported in populations from Northern Europe (Norway and Sweden) 6 and from the United States of America. 7 A thorough examination of previously reported studies of the association of STAT4 with STAT4 gene polymorphism associated with Sjögren's syndrome N Gestermann et al various autoimmune diseases concluded that minor allele frequencies among healthy controls vary, to some extent, by the geographic ancestry, even among the European Caucasians: 22% in Sweden and 23% in Norway, 6 and lower allelic frequencies reported among controls of Spanish (ranging from 19 to 20.8%) 10, 11 or Greek origin (17%). 12 Thus, we considered that a replication study involving pSS patients and controls from the midwest region of Europe was necessary. The significant association of STAT4 rs7582694 C allele with pSS in the exploratory cohort was confirmed in the replication study, which indicated an overall significant association. The STAT4 rs7574865 polymorphism, (instead of STAT4 rs7582694) genotyped in the control group from the replication cohort, is not expected to be a confounding factor because in Caucasian populations, both polymorphisms are in complete LD (r 2 ¼ 1). 13 Minor allele frequencies among controls from the exploratory and the replication cohort were somewhat different (17 and 21%, respectively), suggesting that those Caucasian controls had various European or North African ancestry compounds. Taken together, these data provide a robust replication of the association of STAT4 rs7582694 polymorphism with pSS among French Caucasian patients. The OR of the results for our combined cohorts of pSS patients and control subjects (OR 1.57, 95% CI 1.27-1.93, P ¼ 2.3 Â 10
À5
) is similar to that reported for North European patients (OR 1.41, 95% CI 1.14-1.73) or for US patients (OR 1.46, 95% CI 1.09-1.97). We also confirmed the lack of specific association among patients with or without any anti-SSA/SSB autoantibodies. Moreover, we showed for the first time a high OR for patients homozygous for the STAT4 rs7582694 C allele (OR 2.47, 95% CI 1.47-4.16, P ¼ 6 Â 10
À4
), which suggests a recessive effect of the STAT4 at-risk allele.
To date, two genetic factors are considered as being prominently involved in genetic susceptibility to pSS independent of anti-SSA/SSB antibody status: STAT4 and IRF5. These two genetic associations have been convincingly replicated for Caucasian pSS patients by independent teams. Interestingly, these associations are not limited to patients with specific profiles of autoantibody profiles, in contrast to studies of the human leukocyte antigen class II, which shows significant association of patients with anti-SSA (HLA-DRB1*15) or anti-SSA and anti-SSB (HLA-DRB1*03) antibodies. Moreover, the significant association of both STAT4 and IRF5 polymorphisms has been also reported for other autoimmune diseases or inflammatory conditions, such as systemic sclerosis, 14 rheumatoid arthritis, 15 lupus. 8, 11, [15] [16] [17] [18] Interestingly, all these autoimmune diseases could be, to some extent type 1 IFN driven. This study provides additional data suggesting that STAT4 and IRF5 function independently on pSS genetic susceptibility, with an additive effect but with no epistatic interaction between both genes, which confirms the findings from Nordmark et al. 6 in patients of North European ancestry.
However, the remaining question is the functional consequence of STAT4 rs7582694 polymorphism. This single nucleotide polymorphism is located in the third intron of STAT4 and is expected to be in LD with the true causative single nucleotide polymorphism. Few functional studies of STAT4 rs7582694 polymorphism have been performed. Abelson et al. 8 reported a modest but significant correlation between STAT4 rs7574865 polymorphism (in complete LD with STAT4 rs7582694) and STAT4a mRNA level in PBMCs from 73 healthy volunteers. Sigurdsson et al. 17 reported an increased expression of the risk allele of STAT4b in primary cells of mesenchymal origin (osteoblasts). None of the previous studies has addressed the functional consequences of STAT4 rs7582694 or STAT4 rs7574865 polymorphism among pSS patients. We found no significant association of any genotype with mRNA levels of STAT4a and STA4b among 30 pSS patients. A lack of power does not likely explain the discrepancies between our results and those from Abelson et al. 8 because no trend effect was observed. We wondered whether the functional consequences of STAT4 risk allele might be explained by an environmental upregulation of STAT4 among pSS patients. Such a hypothesis is unlikely because the mRNA level of STAT4 was comparable between patients and healthy controls (data not shown). Thus, the functional relevance of STAT4 rs7582694 is still unclear. The true functional polymorphism is likely to be in high LD with STAT4 rs7582694 polymorphism, but is still unknown, despite a number of studies of STAT4 gene polymorphisms. 13, 15, 16 We explored whether the putative functional polymorphism, in LD with STAT4 rs7582694 polymorphism, could lie within STAT1, which is located close to STAT4. Nevertheless, we found no significant association between STAT1 mRNA level in PBMCs and STAT4 polymorphism.
The most interesting finding of this study is the strong and direct correlation between the mRNA levels of STAT4a and three type 1 IFN-induced genes, which had never been reported before. Such correlation was not observed with STAT4b. Interestingly, a similar functional difference between STAT4a and STAT4b subunits has been reported in mice, in which Stat4b was not as efficient as Stat4a in directly inducing IFNg gene expression. 19 Two hypotheses can be drawn from those results: either STAT4 may be activated after the ligation of type 1 IFN on IFNAR in parallel and independently of type 1 IFN-induced genes, as was previously suggested in mice and in humans, 20, 21 or STAT4 could be an intermediate for induction of type 2 IFN (its classical role) and for inducing the expression of type 1 IFNinduced genes, as was recently suggested by Kariuki et al. 9 This last hypothesis needs further investigation. In conclusion, our results confirm a replicated association of STAT4 polymorphism with pSS in patients from the midwest region of Europe, with a potential recessive effect on disease susceptibility. Our results do not support the functional relevance of the at-risk genotypes on the mRNA levels of STAT4a, STAT4b or STAT1. Unexpectedly, the mRNA levels of STAT4a and type 1 IFN-induced genes were strongly correlated in pSS patients, which supports a possible direct involvement of STAT4 in not only the production of type 2 IFN but also in mediating the effects of type 1 IFN.
Patients and methods
Patients
The exploratory cohort consisted of 186 unrelated patients with pSS, diagnosed according to the AmericanEuropean consensus group criteria 22 (114 (61%) with 
Statistical analysis
Quality of genotype data was verified by testing for Hardy-Weinberg equilibrium in each control sample with the Fisher's exact test at Po0.01. The allele counts in cases and controls were compared by Fisher's exact test to estimate the significance of the association with pSS for the STAT4 rs7582694 polymorphism. Calculation of OR and 95% CI involved the use of GraphPad software Prism 5.0. The risk alleles of STAT4 (rs7582694 C) and IRF5 (CGGGG insertion in IRF5 promoter region) [22] were determined in the exploratory cohort. Observed OR and CIs were computed by the use of epitools library for epidemiology analyses developed for the R statistical software (R Foundation for Statistical Computing, Vienna, Austria). Logistic regression analysis was used to determine the association of the disease status with risk alleles. The logarithm of the OR for pSS was modeled as a linear function of the number of risk alleles computed, 0 risk allele being chosen as the reference. Only eight subjects carried four risk alleles, all in the patient group, so data for subjects with three or four risk alleles were pooled for the analysis. Logistic regression models with STAT4 and IRF5 risk alleles, which were entered as two variables, both with and without interaction, were also tested. The analyses involved the use of the R statistical software.
Analysis of variance was used to determine the difference in the mRNA expression level in relation to STAT4 rs7582694 polymorphism, taking the three possible genotypes as factor levels. The correlations between mRNA levels of STAT4a, STAT4b, STAT1 and type 1 IFNinduced genes were determined by Spearman's nonparametric correlation analyses.
experiments. CMR, NG, AM and XM conducted data analysis. EC conducted statistical analysis. PL was involved in control sample data collection. XP, EH and JEG were involved in patient sample data collection.
